Linda Mileshkin
Linda Mileshkin
Peter MacCallum Cancer Centre
Bekræftet mail på petermac.org
Citeret af
Citeret af
Adjuvant trastuzumab in HER2-positive breast cancer
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ...
New England journal of medicine 365 (14), 1273-1283, 2011
Whole–genome characterization of chemoresistant ovarian cancer
AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ...
Nature 521 (7553), 489-494, 2015
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
Cervical cancer: a global health crisis
W Small Jr, MA Bacon, A Bajaj, LT Chuang, BJ Fisher, MM Harkenrider, ...
Cancer 123 (13), 2404-2412, 2017
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre …
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ...
The lancet oncology 19 (3), 295-309, 2018
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
S Moran, A Martínez-Cardús, S Sayols, E Musulén, C Balañá, ...
The Lancet Oncology 17 (10), 1386-1395, 2016
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ...
Modern pathology 28 (6), 836-844, 2015
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring
L Mileshkin, R Stark, B Day, JF Seymour, JB Zeldis, HM Prince
Journal of Clinical Oncology 24 (27), 4507-4514, 2006
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a …
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ...
The lancet oncology 20 (9), 1273-1285, 2019
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors
JR Infante, DR Camidge, LR Mileshkin, EX Chen, RJ Hicks, D Rischin, ...
Journal of Clinical Oncology 30 (13), 1527-1533, 2012
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
A León-Castillo, SM De Boer, ME Powell, LR Mileshkin, HJ Mackay, ...
Journal of Clinical Oncology 38 (29), 3388, 2020
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre …
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ...
The Lancet Oncology 17 (8), 1114-1126, 2016
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
L Mileshkin, JJ Biagi, P Mitchell, C Underhill, A Grigg, R Bell, ...
Blood 102 (1), 69-77, 2003
Low physical activity levels and functional decline in individuals with lung cancer
CL Granger, CF McDonald, L Irving, RA Clark, K Gough, A Murnane, ...
Lung Cancer 83 (2), 292-299, 2014
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non–small cell lung cancer treated with erlotinib
L Mileshkin, RJ Hicks, BGM Hughes, PLR Mitchell, V Charu, BJ Gitlitz, ...
Clinical Cancer Research 17 (10), 3304-3315, 2011
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for …
FA Eggink, IC Van Gool, A Leary, PM Pollock, EJ Crosbie, L Mileshkin, ...
Oncoimmunology 6 (2), e1264565, 2017
Massively‐parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
RW Tothill, J Li, L Mileshkin, K Doig, T Siganakis, P Cowin, A Fellowes, ...
The Journal of pathology 231 (4), 413-423, 2013
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT InhibitionTargeting CCNE1-Amplified Cancer by CDK2 and AKT …
G Au-Yeung, F Lang, WJ Azar, C Mitchell, KE Jarman, K Lackovic, D Aziz, ...
Clinical Cancer Research 23 (7), 1862-1874, 2017
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix
T Satoh, Y Takei, I Treilleux, M Devouassoux-Shisheboran, J Ledermann, ...
International Journal of Gynecologic Cancer 24 (Supp 3), 2014
Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian CancerResistance to CDK2 Inhibitors in CCNE1-Amplified Cancer
D Etemadmoghadam, G Au-Yeung, M Wall, C Mitchell, M Kansara, ...
Clinical Cancer Research 19 (21), 5960-5971, 2013
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20